Delivering excellence, innovation, and efficiency

X-Chem delivers excellence, innovation and efficiency at each stage of drug discovery. Since 2012, our medicinal chemists have been named as co-inventors on 24 projects, have filed over 100 patents and published more than 65 scientific papers. Our impressive track record includes 17 compounds reaching IND-enabling toxicology studies and seven compounds progressing to Phase I clinical trials or beyond.

Hit → Lead → Candidate: Click through our proven track record of reliability, efficiency and success.

ION CHANNELS

CIBLE :
Sodium Channel Modulator

ZONE DE THÉRAPIE :
Epilepsy

GPCRS

CIBLE :
H4 Antagonist

ZONE DE THÉRAPIE :
Inflammation

TRANSCRIPTION FACTORS

CIBLE :
FOXO1 Inhibitor

ZONE DE THÉRAPIE :
Diabetes

KINASES

CIBLE :
PINK1 Activator

ZONE DE THÉRAPIE :
Neurodégénérescence

PROTEIN PROTEIN INTERACTIONS

CIBLE :
NLRP3 Inhibitor

ZONE DE THÉRAPIE :
Inflammation

GPCRS

CIBLE :
CXCR7 Modulator

ZONE DE THÉRAPIE :
Heart Failure

PROTEIN PROTEIN INTERACTIONS

CIBLE :
KEAP1 Inhibitor

ZONE DE THÉRAPIE :
Neurodégénérescence

GTPASES

CIBLE :
Rac Inhibitor

ZONE DE THÉRAPIE :
Le cancer

EPIGENETIC Regulators

CIBLE :
Bromodomain Inhibitor

ZONE DE THÉRAPIE :
Inflammation and Cancer

EPIGENETIC Regulators

CIBLE :
Bromodomain Inhibitor

ZONE DE THÉRAPIE :
Inflammation and Cancer

EPIGENETIC Regulators

CIBLE :
Bromodomain Inhibitor

ZONE DE THÉRAPIE :
Inflammation and Cancer

EPIGENETIC Regulators

CIBLE :
Bromodomain Inhibitor

ZONE DE THÉRAPIE :
Inflammation and Cancer

EPIGENETIC Regulators

CIBLE :
EED (PRC2) Modulator

ZONE DE THÉRAPIE :
Blood Disorder

GPCRS

CIBLE :
PAR2 Modulator

ZONE DE THÉRAPIE :
Inflammation

ION CHANNELS

CIBLE :
Sodium Channel Modulator

ZONE DE THÉRAPIE :
Epilepsy

LIPIDS

CIBLE :
Ferroptosis Inhibitor

ZONE DE THÉRAPIE :
Neurodégénérescence